Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?

医学 食管切除术 食管癌 倾向得分匹配 放化疗 外科 入射(几何) 癌症 内科学 疾病 吻合 总体生存率 光学 物理
作者
Sheraz R. Markar,Caroline Gronnier,Alain Duhamel,Arnaud Pasquer,Jérémie Thereaux,M. Chalret du Rieu,Jérémie H. Lefèvre,Kathleen Turner,Guillaume Luc,C. Mariette
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:33 (33): 3866-3873 被引量:189
标识
DOI:10.1200/jco.2014.59.9092
摘要

Purpose The aim of this large multicenter study was to assess the impact of salvage esophagectomy after definitive chemoradiotherapy (SALV) on clinical outcome. Patients and Methods Data from consecutive adult patients undergoing resection for esophageal cancer in 30 European centers from 2000 to 2010 were collected. First, groups undergoing SALV (n = 308) and neoadjuvant chemoradiotherapy followed by planned esophagectomy (NCRS; n = 540) were compared. Second, patients who benefited from SALV for persistent (n = 234) versus recurrent disease (n = 74) were compared. Propensity score matching and multivariable analyses were used to compensate for differences in some baseline characteristics. Results SALV versus NCRS groups: In-hospital mortality was similar in both groups (8.4% v 9.3%). The only significant differences in complications were seen for anastomotic leak (17.2% v 10.7%; P = .007) and surgical site infection, which were both more frequent in the SALV group. At 3 years, groups had similar overall (43.3% v 40.1%; P = .542) and disease-free survival (39.2% v 32.8%; P = .232) after matching, along with a similar recurrence pattern. Persistent versus recurrent disease groups: There were no significant differences between groups in incidence of in-hospital mortality or major complications. At 3 years, overall (40.9% v 56.2%; P = .046) and disease-free survival (36.6% v 51.6%; P = .095) were lower in the persistent disease group. Conclusion The results of this large multicenter study from the modern era suggest that SALV can offer acceptable short- and long-term outcomes in selected patients at experienced centers. Persistent cancer after definitive chemoradiotherapy seems to be more biologically aggressive, with poorer survival compared with recurrent cancer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
krsL发布了新的文献求助10
刚刚
和谐小馒头的应助被稳重紫蓝采纳,获得10
1秒前
DAI发布了新的文献求助10
1秒前
飞快的孱发布了新的文献求助10
1秒前
1秒前
ChenHao完成签到,获得积分10
1秒前
Hyz发布了新的文献求助10
2秒前
六六发布了新的文献求助10
2秒前
脑洞疼的应助被小迪采纳,获得10
2秒前
超级无敌发布了新的文献求助30
3秒前
3秒前
3秒前
胖虎完成签到,获得积分10
3秒前
科研通AI2S的应助被牧百川采纳,获得10
4秒前
4秒前
4秒前
4秒前
as_eichi发布了新的文献求助30
5秒前
5秒前
xieyangyu发布了新的文献求助10
5秒前
浦肯野发布了新的文献求助10
6秒前
6秒前
minmin完成签到,获得积分10
6秒前
Csy发布了新的文献求助10
6秒前
7秒前
777发布了新的文献求助10
7秒前
8秒前
杨宝仪完成签到,获得积分10
8秒前
8秒前
Nature发布了新的文献求助10
8秒前
Li656943234完成签到,获得积分10
9秒前
9秒前
细心大碗完成签到,获得积分10
9秒前
9秒前
张伟发布了新的文献求助10
9秒前
mlg1552003发布了新的文献求助10
10秒前
陈冠羽发布了新的文献求助10
10秒前
昊儿虫完成签到 ,获得积分10
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182977
求助须知:如何正确求助?哪些是违规求助? 9572322
关于积分的说明 21824168
捐赠科研通 7779612
什么是DOI,文献DOI怎么找? 3433774
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971